

BARRIE WARD AND JAAP BLAAK APPOINTED TO SUPERVISORY BOARD

Leiden, The Netherlands, May 23, 2007. Biotech company Pharming Group NV (“Pharming” or “the Company”) (Euronext: PHARM) today announced that its Shareholders have appointed Messrs. Barrie Ward and Jaap Blaak to the Supervisory Board of the Company for a period of four years. At the same meeting, Mr. G. Verhagen resigned from his position as a Supervisory Director.

Mr. Blaak (66), Dutch citizen, has an impressive track record in managerial positions in the Netherlands, USA, Germany and Singapore. In 1983, he was involved with the foundation of the MIP Equity Fund, one of the largest venture capital groups in Europe, and was appointed CEO in 1986. During the lifetime of the fund MIP invested in several life sciences companies that became active in The Netherlands (including Centocor, Mogen and EuroCetus/Chiron). Since 1996, Mr. Blaak is president and owner of Tailwind, a company investing in early stage life science companies.

Dr. Ward (68), UK citizen, has a broad international network and experience in managing and financing biopharmaceutical companies. He has held senior management positions in the UK, USA and Singapore at several pharmaceutical and biotechnology companies, including Glaxo, the Virus Research Institute, Avant Immunotherapeutics and KuDOS Pharmaceuticals. His most recent position was CEO of KuDOS Pharmaceuticals Ltd., which was sold to Astra-Zeneca in 2006.

Both Dr. Ward and Mr. Blaak serve as independent Board members and do not hold shares or options in the Company.

Mr. Ger Verhagen (77), who has served on Pharming's Supervisory Board since February 2002, has resigned from his position as a Board member as of today.

The minutes of the Annual General Meeting of Shareholders will be published on the Company's website within three months.

Background on Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, <http://www.pharming.com> and on <http://www.dnage.nl>.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker

Investor Voice

T: +31 (0)6 537 499 59

T: +31 (0)71 52 47 400

Rein Strijker

Pharming Group NV

T: +31 (0)71 52 47 400